KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Other financing activities (2016 - 2025)

Thermo Fisher Scientific's Other financing activities history spans 17 years, with the latest figure at $91.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 635.29% year-over-year to $91.0 million, compared with a TTM value of $90.0 million through Dec 2025, down 53.85%, and an annual FY2025 reading of $90.0 million, down 53.85% over the prior year.
  • Other financing activities for Q4 2025 was $91.0 million at Thermo Fisher Scientific, up from -$4.0 million in the prior quarter.
  • The five-year high for Other financing activities was $110.0 million in Q1 2024, with the low at -$42.0 million in Q2 2025.
  • Average Other financing activities over 5 years is $19.8 million, with a median of $19.0 million recorded in 2021.
  • Year-over-year, Other financing activities crashed 270.0% in 2022 and then soared 775.0% in 2024.
  • Tracing TMO's Other financing activities over 5 years: stood at $79.0 million in 2021, then plummeted by 74.68% to $20.0 million in 2022, then decreased by 30.0% to $14.0 million in 2023, then crashed by 221.43% to -$17.0 million in 2024, then skyrocketed by 635.29% to $91.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Other financing activities are $91.0 million (Q4 2025), -$4.0 million (Q3 2025), and -$42.0 million (Q2 2025).